The AIDS Clinical Trials Group (ACTG) study A5303 investigated the associations between neuropsychological performance (NP) and inflammatory biomarkers in HIV-infected participants. Fifteen NP tests were administered at baseline and week 48 to 233 ART naïve participants randomized to maraviroc- or tenofovir-containing ART. Neurocognition correlated modestly with markers of lymphocyte activation and inflammation pre-ART (percent CD38+/HLA-DR+(CD4+) (r = - 0.22, p = 0.02) and percent CD38+/HLA-DR+(CD8+) (r = - 0.25, p = 0.02)), and with some monocyte subsets during ART (r = 0.25, p = 0.02). Higher interleukin-6 and percent CD38+/HLA-DR+(CD8+) were independently associated with worse severity of HIV-associated neurocognitive disorders (HAND) (p = 0.04 and 0.01, respectively). More studies to identify HAND biomarkers are needed.

中文翻译：

---

HIV治疗之前和治疗期间，系统性生物标志物与神经认知功能之间的相关性有限。

艾滋病临床试验小组（ACTG）的研究A5303研究了HIV感染者的神经心理表现（NP）与炎症生物标志物之间的关联。在基线和第48周至233名首次接受抗病毒药物的马拉维罗或替诺福韦的初次接受治疗的参与者中进行了15次NP测试。神经认知与ART前淋巴细胞活化和炎症标记物相关（CD38 + / HLA-DR +（CD4 +）百分比（r =-0.22，p = 0.02）和CD38 + / HLA-DR +（CD8 +）百分比（r =-0.25，p = 0.02），并且在ART期间存在一些单核细胞亚群（r = 0.25，p = 0.02）。白细胞介素-6的升高和CD38 + / HLA-DR +（CD8 +）的百分数与HIV相关的神经认知障碍（HAND）的严重程度独立相关（分别为p = 0.04和0.01）。需要更多的研究来鉴定HAND生物标志物。